The National Community Oncology Dispensing Association has announced the addition of hematologist and medical oncologist Barry D. Brooks, MD, to its executive council in April.
Barry D. Brooks, MD
Barry D. Brooks, MD
The National Community Oncology Dispensing Association (NCODA) has announced the addition of hematologist and medical oncologist Barry D. Brooks, MD, to its executive council in April.
“Being part of NCODA is a great honor. I believe NCODA will do for oncology dispensing what the Community Oncology Alliance has done for community oncology by improving access to oral oncology drugs for America’s cancer patients and giving patients a voice in Washington,” said Brooks.
For the past 17 years, Brooks, a clinical associate professor at the University of Texas Health Science Center, Texas Oncology, has been a physician-lead on US Oncology’s Drug Contracting Committee. Additionally, he served as chair of Pharmacy and Therapeutics at US Oncology from 2011 to 2018 and currently serves as Medical Director of Oral Oncolytics.
Brooks received his medical degree from the University of Texas Southwestern Medical School and did his medical residency in internal medicine, as well as a hematology/oncology fellowship, with Parkland Memorial Hospital and Dallas VA Hospital.
“Dr Brooks, in addition to being an outstanding medical oncologist, is a dynamic individual who will bring a great deal of insight from a physician’s perspective to our NCODA initiatives” said Jim Schwartz, NCODA President and Executive Council Chair.
Oncology Experts at NCODA Provide Resources to Improve Patient Understanding and Outcomes
September 3rd 2021Clinicians affiliated with the National Community Oncology Dispensing Association, Inc have launched the Intravenous Cancer Treatment Education website, as educational resource for patients.
Read More
NCODA Patient Surveys Support the Need for Medically-Integrated Pharmacies
May 3rd 2019The NCODA Patient Satisfaction Surveys aim to evaluate overall satisfaction with the pharmacy model from which patients receive therapy, convenience, timing to receive drug, interaction with staff, and financial assistance if available.
Read More
Patient Adherence, a Challenge of Oral Chemotherapy
January 21st 2019Advances in oral chemotherapy are radically changing the way doctors, pharmacists, and their patients manage cancer, yet oral chemotherapy requires the patients themselves to correctly administer the drug, causing issues in patient adherence.<br />
Read More
The Benefits of Medically Integrated Dispensing for Cancer Drugs
January 18th 2019At practices with their own pharmacies, many patients are now given the option of picking up prescriptions directly from the clinic, known as medically integrated dispensing. Proponents of this method believe that it provides for better patient outcomes, allows for better tracking of patient adherence, and is substantially more cost effective.
Read More